An international collaborative study to establish the WHO 4th International Standard for Streptokinase: communication from the SSC of the ISTH.

An international collaborative study to establish the WHO 4th International Standard for Streptokinase: communication from the SSC of the ISTH. J Thromb Haemost. 2020 Feb 29;: Authors: Locke M, Rigsby P, Longstaff C, Fibrinolysis subcommittee Abstract Streptokinase is used worldwide as a cost-effective treatment for acute myocardial infarction (AMI). Manufacturers use the WHO International Standard (IS) for Streptokinase to potency label their products, ensuring consistent, safe, and effective dosing. Stocks of the 3rd IS for Streptokinase (coded 00/464) are running low, and an international collaborative study was organised to calibrate a replacement. A total of 15 laboratories from 9 countries took part, using chromogenic and/or fibrin clot lysis methods to determine the potency of two candidate preparations, coded 16/356 (sample B) and 16/358 (sample C), relative to the 3rd IS (00/464). A third sample (88/824, sample A) which was used in the collaborative studies to establish the 2nd and 3rd IS, was also included. There was good agreement in potency estimates from different assay methods, and low variability both within and between laboratories. Long-term stability modelling indicated the candidates are very stable. Comparison of potency estimates for 88/824 (sample A) with potencies calculated in previous studies revealed a variability of only 1.9 % over the course of three collaborative studies spanning 30 years and more than 50...
Source: Thrombosis and Haemostasis - Category: Hematology Authors: Tags: J Thromb Haemost Source Type: research